Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy

A.L. Noordhof; R.A.M. Damhuis; L.E.L. Hendriks; A.J. de Langen; W. Timens; B.J.W. Venmans; W.H. van Geffen

doi:10.1016/j.lungcan.2021.04.001

Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy

A.L. Noordhof, R.A.M. Damhuis, L.E.L. Hendriks, A.J. de Langen, W. Timens, B.J.W. Venmans, W.H. van Geffen^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Web of Science)

Original language	English
Pages (from-to)	163-169
Number of pages	7
Journal	Lung Cancer
Volume	155
DOIs	https://doi.org/10.1016/j.lungcan.2021.04.001
Publication status	Published - 1 May 2021

Keywords

Non-small cell lung cancer
Kirsten rat sarcoma
Mono-immunotherapy
PREDICTIVE-VALUE
CANCER
EFFICACY
INHIBITORS
DOCETAXEL
SURVIVAL
THERAPY

Access to Document

10.1016/j.lungcan.2021.04.001

Cite this

@article{362f0094c77c498d99dd9e6879c64335,

title = "Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy",

keywords = "Non-small cell lung cancer, Kirsten rat sarcoma, Mono-immunotherapy, PREDICTIVE-VALUE, CANCER, EFFICACY, INHIBITORS, DOCETAXEL, SURVIVAL, THERAPY",

author = "A.L. Noordhof and R.A.M. Damhuis and L.E.L. Hendriks and {de Langen}, A.J. and W. Timens and B.J.W. Venmans and {van Geffen}, W.H.",

year = "2021",

month = may,

day = "1",

doi = "10.1016/j.lungcan.2021.04.001",

language = "English",

volume = "155",

pages = "163--169",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy. / Noordhof, A.L.; Damhuis, R.A.M.; Hendriks, L.E.L.; de Langen, A.J.; Timens, W.; Venmans, B.J.W.; van Geffen, W.H.

In: Lung Cancer, Vol. 155, 01.05.2021, p. 163-169.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy

AU - Noordhof, A.L.

AU - Damhuis, R.A.M.

AU - Hendriks, L.E.L.

AU - de Langen, A.J.

AU - Timens, W.

AU - Venmans, B.J.W.

AU - van Geffen, W.H.

PY - 2021/5/1

Y1 - 2021/5/1

KW - Non-small cell lung cancer

KW - Kirsten rat sarcoma

KW - Mono-immunotherapy

KW - PREDICTIVE-VALUE

KW - CANCER

KW - EFFICACY

KW - INHIBITORS

KW - DOCETAXEL

KW - SURVIVAL

KW - THERAPY

U2 - 10.1016/j.lungcan.2021.04.001

DO - 10.1016/j.lungcan.2021.04.001

M3 - Article

C2 - 33838467

VL - 155

SP - 163

EP - 169

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -